Peginesatide safe for anemia in patients undergoing dialysis

January 24, 2013
Peginesatide safe for anemia in patients undergoing dialysis
Peginesatide, a peptide-based erythropoiesis-stimulating agent, is safe and effective in patients with advanced chronic kidney disease and anemia as long as they are undergoing dialysis, according to two studies published in the Jan. 24 issue of The New England Journal of Medicine.

(HealthDay)—Peginesatide, a peptide-based erythropoiesis-stimulating agent, is safe and effective in patients with advanced chronic kidney disease and anemia as long as they are undergoing dialysis, according to two studies published in the Jan. 24 issue of The New England Journal of Medicine.

In the first study, Steven Fishbane, M.D., from the Hofstra North Shore-LIJ School of Medicine in Great Neck, N.Y., and colleagues analyzed data from 1,418 patients with and anemia undergoing who were treated with peginesatide or epoetin as part of two randomized open-label trials. The researchers found that peginesatide was non-inferior to epoetin in its ability to maintain hemoglobin levels, and the cardiovascular safety was similar in both groups.

In the second study, Iain C. Macdougall, M.D., from King's College Hospital in London, and colleagues analyzed data from 983 patients with advanced and anemia not undergoing dialysis who were treated with peginesatide or darbepoetin as part of two randomized open-label trials. The researchers found that peginesatide was non-inferior to darbepoetin in its ability to increase and maintain , but cardiovascular events and mortality were higher in patients receiving peginesatide.

"Peginesatide can be used for anemia correction in patients undergoing hemodialysis, in which case its efficacy profile is similar to the profiles of established erythropoiesis-stimulating agents, but concerns remain about its safety in patients not receiving hemodialysis," writes the author of an accompanying editorial.

Several authors from the first study disclosed financial ties to pharmaceutical companies, including Affymax and Takeda, which funded both studies.

Explore further: Omontys approved for anemic people with kidney disease

More information: Full Text - Fishbane (subscription or payment may be required)
Full Text - Macdougall (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Omontys approved for anemic people with kidney disease

March 27, 2012
(HealthDay) -- Omontys (peginesatide) has been approved by the U.S. Food and Drug Administration to treat anemia in adults who require dialysis due to chronic kidney disease.

New drug labels for kidney disease patients -- what do they mean?

January 19, 2012
The U.S. Food and Drug Administration (FDA) recently recommended that clinicians be more conservative when they prescribe chronic kidney disease (CKD) patients with drugs that treat red blood cell deficiencies. But the drug ...

Fixing common blood disorder would make kidney transplants more successful

December 22, 2011
Correcting anemia, a red blood cell deficiency, can preserve kidney function in many kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). ...

Recommended for you

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.